The lack of either IRF9, or STAT2, has surprisingly little effect on human natural killer cell development and function.
Ane Calvo-ApalategiMarta López NevadoLuz Yadira Bravo-GallegoLuis Ignacio González-GranadoLuis M AllendeRebeca Rodríguez PenaEduardo López-GranadosHugh T ReyburnPublished in: Immunology (2024)
Analysis of genetically defined immunodeficient patients allows study of the effect of the absence of specific proteins on human immune function in real-world conditions. Here we have addressed the importance of type I interferon signalling for human NK cell development by studying the phenotype and function of circulating NK cells isolated from patients suffering primary immunodeficiency disease due to mutation of either the human interferon regulatory factor 9 (IRF9) or the signal transducer and activator of transcription 2 (STAT2) genes. IRF9, together with phosphorylated STAT1 and STAT2, form a heterotrimer called interferon stimulated gene factor 3 (ISGF3) which promotes the expression of hundreds of IFN-stimulated genes that mediate antiviral function triggered by exposure to type I interferons. IRF9- and STAT2-deficient patients are unable to respond efficiently to stimulation by type I interferons and so our experiments provide insights into the importance of type I interferon signalling and the consequences of its impairment on human NK cell biology. Surprisingly, the NK cells of these patients display essentially normal phenotype and function.
Keyphrases
- nk cells
- end stage renal disease
- endothelial cells
- dendritic cells
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- immune response
- induced pluripotent stem cells
- gene expression
- transcription factor
- poor prognosis
- mesenchymal stem cells
- pluripotent stem cells
- cell therapy
- nuclear factor
- bioinformatics analysis